Citigroup
OTLK icon

Citigroup’s Outlook Therapeutics OTLK Stock Holding History

Citigroup’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,554
Closed -$2.46K – 6271
2025
Q4 		$2.46K Sell
1,554
-14,424
-90% -$23K ﹤0.01% 5421
2025
Q3 		$16.9K Sell
15,978
-1,221
-7% -$2.11K ﹤0.01% 4873
2025
Q2 		$27.5K Sell
17,199
-561
-3% -$894 ﹤0.01% 5001
2025
Q1 		$21.7K Buy
17,760
+2,731
+18% +$4.79K ﹤0.01% 5076
2024
Q4 		$28.4K Buy
15,029
+2,693
+22% +$11.1K ﹤0.01% 5216
2024
Q3 		$65.9K Buy
12,336
+10,003
+429% +$73.2K ﹤0.01% 4931
2024
Q2 		$17.2K Buy
2,333
+778
+50% +$6.25K ﹤0.01% 5040
2024
Q1 		$18.6K Buy
1,555
+341
+28% +$2.76K ﹤0.01% 5052
2023
Q4 		$9.56K Buy
1,214
+1,200
+8,571% +$10.1K ﹤0.01% 5203
2023
Q3 		$64 Sell
14
-2,296
-99% -$50.8K ﹤0.01% 5501
2023
Q2 		$80.4K Buy
+2,310
New +$63K ﹤0.01% 4351
2023
Q1 		– Sell
-40
Closed -$862 – 5753
2022
Q4 		$862 Sell
40
-50
-56% -$1.09K ﹤0.01% 5425
2022
Q3 		$2K Sell
90
-298
-77% -$6.93K ﹤0.01% 5515
2022
Q2 		$8K Buy
388
+183
+89% +$5.26K ﹤0.01% 5456
2022
Q1 		$7K Sell
205
-942
-82% -$29.4K ﹤0.01% 5696
2021
Q4 		$31K Buy
1,147
+575
+101% +$20.5K ﹤0.01% 5255
2021
Q3 		$25K Buy
572
+364
+175% +$17.6K ﹤0.01% 5132
2021
Q2 		$10K Buy
+208
New +$9.65K ﹤0.01% 5665

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Citigroup's OTLK Position: Q1 2026 in Review

Citigroup sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 1,554 shares — an estimated $2.46K sold.

Citigroup first reported a position in OTLK in Q2 2021 and held it in 18 quarters. The position peaked at $80.4K in Q2 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Citigroup reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1,554 Outlook Therapeutics shares in Q1 2026, an estimated $2.46K.
  • Citigroup first reported a position in Outlook Therapeutics in Q2 2021 and held it in 18 quarters.
  • Citigroup's Outlook Therapeutics position peaked at $80.4K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.